Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:KITE's Cash-to-Debt is ranked higher than
72% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. NAS:KITE: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:KITE' s Cash-to-Debt Range Over the Past 10 Years
Min: 34.6  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.78
NAS:KITE's Equity-to-Asset is ranked higher than
65% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:KITE: 0.78 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:KITE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.78  Med: 0.83 Max: 0.87
Current: 0.78
0.78
0.87
Piotroski F-Score: 3
Altman Z-Score: 30.00
Beneish M-Score: -3.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -1105.16
NAS:KITE's Operating Margin % is ranked lower than
77% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. NAS:KITE: -1105.16 )
Ranked among companies with meaningful Operating Margin % only.
NAS:KITE' s Operating Margin % Range Over the Past 10 Years
Min: -1232.24  Med: -917.29 Max: -602.33
Current: -1105.16
-1232.24
-602.33
Net Margin % -1117.44
NAS:KITE's Net Margin % is ranked lower than
78% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. NAS:KITE: -1117.44 )
Ranked among companies with meaningful Net Margin % only.
NAS:KITE' s Net Margin % Range Over the Past 10 Years
Min: -1204.65  Med: -896.84 Max: -589.02
Current: -1117.44
-1204.65
-589.02
ROE % -60.72
NAS:KITE's ROE % is ranked lower than
62% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. NAS:KITE: -60.72 )
Ranked among companies with meaningful ROE % only.
NAS:KITE' s ROE % Range Over the Past 10 Years
Min: -60.72  Med: -32.79 Max: -20.78
Current: -60.72
-60.72
-20.78
ROA % -50.22
NAS:KITE's ROA % is ranked lower than
63% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:KITE: -50.22 )
Ranked among companies with meaningful ROA % only.
NAS:KITE' s ROA % Range Over the Past 10 Years
Min: -50.22  Med: -28.93 Max: -18.85
Current: -50.22
-50.22
-18.85
ROC (Joel Greenblatt) % -777.81
NAS:KITE's ROC (Joel Greenblatt) % is ranked lower than
58% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. NAS:KITE: -777.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:KITE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -15129.41  Med: -2848.18 Max: -627.5
Current: -777.81
-15129.41
-627.5
3-Year EBITDA Growth Rate 190.10
NAS:KITE's 3-Year EBITDA Growth Rate is ranked higher than
98% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. NAS:KITE: 190.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:KITE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 95.05 Max: 190.1
Current: 190.1
0
190.1
3-Year EPS without NRI Growth Rate 191.70
NAS:KITE's 3-Year EPS without NRI Growth Rate is ranked higher than
99% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. NAS:KITE: 191.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:KITE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 95.85 Max: 191.7
Current: 191.7
0
191.7
GuruFocus has detected 3 Warning Signs with Kite Pharma Inc NAS:KITE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:KITE's 30-Y Financials

Financials (Next Earnings Date: 2018-02-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

KITE Guru Trades in Q4 2016

Steven Cohen 244,722 sh (New)
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
» More
Q1 2017

KITE Guru Trades in Q1 2017

Leon Cooperman 53,761 sh (New)
John Hussman 35,000 sh (New)
Columbia Wanger 451,674 sh (New)
Steven Cohen 819,900 sh (+235.03%)
» More
Q2 2017

KITE Guru Trades in Q2 2017

Andreas Halvorsen 480,155 sh (New)
Paul Tudor Jones 5,055 sh (New)
Joel Greenblatt 5,320 sh (New)
Steven Cohen 400,000 sh (unchged)
Leon Cooperman Sold Out
John Hussman Sold Out
Columbia Wanger 368,254 sh (-18.47%)
Steven Cohen 437,969 sh (-46.58%)
» More
Q3 2017

KITE Guru Trades in Q3 2017

Jim Simons 778,300 sh (New)
Prem Watsa 6,100 sh (New)
Mario Gabelli 193,350 sh (New)
Joel Greenblatt 61,725 sh (+1060.24%)
Columbia Wanger Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Andreas Halvorsen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:KITE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2017-09-30 New Buy0.22%$101.13 - $179.74 $ 179.7930%193,350
Joel Greenblatt 2017-09-30 Add 1060.24%0.15%$101.13 - $179.74 $ 179.7930%61,725
Prem Watsa 2017-09-30 New Buy0.09%$101.13 - $179.74 $ 179.7930%6,100
Joel Greenblatt 2017-06-30 New Buy0.01%$70.59 - $102.87 $ 179.79121%5,320
Leon Cooperman 2017-06-30 Sold Out 0.17%$70.59 - $102.87 $ 179.79121%0
Leon Cooperman 2017-03-31 New Buy0.17%$45.91 - $85.92 $ 179.79191%53,761
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 2834
Compare:NAS:ALNY, NAS:SGEN, HKSE:01177, OCSE:GEN, NAS:JAZZ, NAS:EXEL, NAS:ALKS, NAS:IONS, XBRU:UCB, HKSE:02269, NAS:BLUE, NAS:TSRO, NAS:BMRN, NAS:BIVV, NAS:JUNO, NAS:NBIX, SZSE:002252, NAS:UTHR, XAMS:GLPG, XKRX:128940 » details
Traded in other countries:KT5.Germany,
Headquarter Location:USA
Kite Pharma Inc is a clinical-stage biopharmaceutical company. It is engaged in the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells.

Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products. In partnership with the National Cancer Institute through a cooperative research and development agreement, Kite is advancing a pipeline of proprietary product candidates, both chimeric antigen receptor and T-cell receptor products, targeting a wide range of cancer indications. The company also has a strategic collaboration with Amgen to develop and commercialize next-generation CAR-T therapies.

Top Ranked Articles about Kite Pharma Inc

Mario Gabelli’s Top 5 New Buys for the 3rd Quarter Guru releases quarterly portfolio
GAMCO Investors leader Mario Gabelli (Trades, Portfolio) added 45 stocks to his portfolio in the third quarter. Read more...
5 Companies Achieve 52-Week Highs International Flavors & Fragrances leads milestone list
According to GuruFocus' list, these stocks have reached their 52-week highs. Read more...
Let’s Talk About CAR-T A quick overview of treatment and the major players in bringing promising cancer-fighting technologies to market
For those interested in staying up to date with the latest developments in biotechnology it is impossible to overlook the developments of chimeric antigen receptor therapy (CAR-T) and the potential it holds for treating cancer. The most pivotal moment came on Aug. 30 when Novartis (NVS) announced approval for Kymriah™ (tisagenlecleucel) for treating children and young adults with B-cell acute lymphoblastic leukemia (ALL) that is refractory or has relapsed at least twice. Read more...
Andreas Halvorsen Scoops Up Abeona Therapeutics Guru invests in biopharmaceutical company
Viking Global Investors LP Chief Investment Officer Andreas Halvorsen (Trades, Portfolio) established a stake in Abeona Therapeutics Inc. (NASDAQ:ABEO) on Sept. 22, according to GuruFocus real-time picks. Read more...
Multiple Companies Achieve Yearly Highs 5 companies have managed to hit 52-week milestones
According to GuruFocus' list, these stocks have reached their 52-week highs. Read more...
Novartis and the Future of Gene Therapy The company recently became the first to market a gene therapy for cancer
Gene therapy is now, finally, a new weapon in our arsenal against cancer partly thanks to, of all things, the HIV virus. The world’s first chimeric antigen receptor T-cell (CAR-T) treatment was approved by the Food and Drug Administration at the end of last month, a treatment developed by one Dr. Carl June at University of Pennsylvania in partnership with Novatris AG (NYSE:NVS). Read more...
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Kite Pharma, Inc. - KITE
Harwood Feffer LLP Announces Investigation of Kite Pharma, Inc.
UQM Technologies, Kite Pharma Jump on Monday Kite, Gilead gain on acquisition news
The U.S. stock market opened mixed with investors looking to the impact of Hurricane Harvey. Read more...
Options Trader Alert: Covered-call reports released for Caterpillar Inc., Juno Therapeutics Inc, Kite Pharma, Southwest Airlines Co. and Ulta Salon Cosmetics & Fragrance Inc.

Ratios

vs
industry
vs
history
PB Ratio 14.47
KITE's PB Ratio is ranked lower than
88% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. KITE: 14.47 )
Ranked among companies with meaningful PB Ratio only.
KITE' s PB Ratio Range Over the Past 10 Years
Min: 3.28  Med: 5.82 Max: 14.47
Current: 14.47
3.28
14.47
PS Ratio 292.34
KITE's PS Ratio is ranked lower than
93% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. KITE: 292.34 )
Ranked among companies with meaningful PS Ratio only.
KITE' s PS Ratio Range Over the Past 10 Years
Min: 92.83  Med: 144.69 Max: 1057.21
Current: 292.34
92.83
1057.21
EV-to-EBIT -27.07
KITE's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. KITE: -27.07 )
Ranked among companies with meaningful EV-to-EBIT only.
KITE' s EV-to-EBIT Range Over the Past 10 Years
Min: -54.4  Med: -14.3 Max: -6.6
Current: -27.07
-54.4
-6.6
EV-to-EBITDA -28.08
KITE's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. KITE: -28.08 )
Ranked among companies with meaningful EV-to-EBITDA only.
KITE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -55  Med: -14.95 Max: -6.8
Current: -28.08
-55
-6.8
EV-to-Revenue 296.63
KITE's EV-to-Revenue is ranked lower than
88% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. KITE: 296.63 )
Ranked among companies with meaningful EV-to-Revenue only.
KITE' s EV-to-Revenue Range Over the Past 10 Years
Min: 72.6  Med: 123.1 Max: 910.9
Current: 296.63
72.6
910.9
Current Ratio 9.01
KITE's Current Ratio is ranked higher than
77% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. KITE: 9.01 )
Ranked among companies with meaningful Current Ratio only.
KITE' s Current Ratio Range Over the Past 10 Years
Min: 7.65  Med: 13.72 Max: 54.78
Current: 9.01
7.65
54.78
Quick Ratio 9.01
KITE's Quick Ratio is ranked higher than
78% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. KITE: 9.01 )
Ranked among companies with meaningful Quick Ratio only.
KITE' s Quick Ratio Range Over the Past 10 Years
Min: 7.65  Med: 13.72 Max: 54.78
Current: 9.01
7.65
54.78

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -19.60
KITE's 3-Year Average Share Buyback Ratio is ranked lower than
62% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. KITE: -19.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KITE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -19.6  Med: -9.8 Max: 0
Current: -19.6
-19.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 17.59
KITE's Price-to-Net-Cash is ranked lower than
75% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. KITE: 17.59 )
Ranked among companies with meaningful Price-to-Net-Cash only.
KITE' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.62  Med: 6.73 Max: 17.59
Current: 17.59
4.62
17.59
Price-to-Net-Current-Asset-Value 17.09
KITE's Price-to-Net-Current-Asset-Value is ranked lower than
78% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. KITE: 17.09 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
KITE' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.48  Med: 6.7 Max: 17.09
Current: 17.09
4.48
17.09
Price-to-Tangible-Book 15.15
KITE's Price-to-Tangible-Book is ranked lower than
84% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. KITE: 15.15 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
KITE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.08  Med: 5.83 Max: 15.15
Current: 15.15
4.08
15.15
Price-to-Median-PS-Value 2.02
KITE's Price-to-Median-PS-Value is ranked lower than
83% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. KITE: 2.02 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
KITE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.69  Med: 1.05 Max: 5.86
Current: 2.02
0.69
5.86
Earnings Yield (Greenblatt) % -3.69
KITE's Earnings Yield (Greenblatt) % is ranked higher than
63% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. KITE: -3.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
KITE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -15.2  Med: -7 Max: -1.8
Current: -3.69
-15.2
-1.8

More Statistics

Revenue (TTM) (Mil) $32.14
EPS (TTM) $ -6.91
Short Percentage of Float7.44%
52-Week Range $39.82 - 179.95
Shares Outstanding (Mil)57.36

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 46 239 645 1,144
EPS ($) -5.82 -4.29 -0.82 2.98
EPS without NRI ($) -5.82 -4.29 -0.82 2.98
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}